Part 2: Post-transplant Lymphoproliferative Disorders

Namrata M. Shah, MD, MPH

Hematology/Oncology Fellow, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 3

Which of the following are important risk factors that contribute to the development of PTLD?

  •   Age at transplant
  •   Exposure to specific immune-suppressing medications such as tacrolimus,
    antilymphocyte antibodies, and T-cell depleting antibodies
  •   Primary Epstein-Barr virus (EBV) infection after transplantation
  •   Recipient pretransplant EBV seronegativity
  •   All of the above

Updated 05/17/2013 • jdw | Copyright ©2018 Turner White Communications